BEROCCA PN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEROCCA PN is an injectable small-molecule formulation approved by Roche in 1947, representing a legacy vitamin/nutritional product administered via injection. The specific indication and mechanism of action are not currently documented in available data. Patient population and therapeutic use require clarification from primary product labeling.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); small team of 3 linked positions suggests declining investment and consolidation phase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 3 linked positions with primary concentration in R&D research associate roles suggests a small, specialized team managing a legacy product. Career trajectory on this product is limited due to LOE approaching status and minimal pipeline activity.
Research Associate
Research & Development
Worked on BEROCCA PN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.